
A phase I study was performed on a newly developed zzso agent, zzso zzso zzso The study was started at an initial dose of 1 zzso 25 zzso and gradually increased up to zzso 800 zzso With single (35 zzso and zzso zzso zzso administration, the zzso factor was found to be zzso stool, remarkable decrease in zzso content, and strong zzso and breast zzso The maximum tolerated dose zzso was concluded to be around 700 to 800 zzso With long-term administration (the longest term, 20 weeks, 36 zzso the zzso factor was concluded to be a decrease in the peripheral zzso count when the total amount administered reached about 10 zzso Side effects on the zzso system due to this agent, such as zzso zzso and zzso were zzso In addition, zzso and zzso bleeding due to released zzso were also seen, especially in the case of long-term zzso 

